2. Academic Validation
  3. Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

  • Bioorg Med Chem. 2024 Nov 1:113:117927. doi: 10.1016/j.bmc.2024.117927.
Tongtong Kang 1,  Simin Sun 1,  Huimin Wang 1,  Jinyu Liu 1,  Xiaoyang Li 2,  Yuqi Jiang 3
Affiliations

Affiliations

  • 1 Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.
  • 2 Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China; Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China; Marine Biomedical Research Institute of Qingdao, Qingdao, Shandong 266071, China.
  • 3 Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China; Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China; Marine Biomedical Research Institute of Qingdao, Qingdao, Shandong 266071, China. Electronic address: jiangyuqi@ouc.edu.cn.
PMID: 39317006 DOI: 10.1016/j.bmc.2024.117927
Abstract

The aberrant activation of the NLRP3 inflammasome has been implicated in the pathogenesis of numerous inflammation-related diseases. Development of NLRP3 inflammasome inhibitors is expected to provide a new strategy for the treatment of these diseases. Herein, a novel series of diphenylamine derivatives were designed based on the lead compounds H20 and H28, and the preliminary structure-activity relationship was studied. The representative compound 19 displayed significantly higher inhibitory activity against NLRP3 inflammasome compared to lead compounds H20 and H28, with an IC50 of 0.34 μM. Mechanistic studies indicated that compound 19 directly targets the NLRP3 protein (KD: 0.45 μM), blocking the assembly and activation of the NLRP3 inflammasome, leading to anti-inflammatory effects and inhibition of cellular Pyroptosis. Our findings indicated that compound 19 is a promising NLRP3 Inhibitor and could potentially serve as a lead compound for further optimization.

Keywords

Anti-inflammatory; Diphenylamine; NLRP3 inflammasome; NLRP3 inhibitors; Pyroptosis.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z